Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
- Status
- COMPLETED
- Phase
- PHASE2
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
- Status
- WITHDRAWN
- Phase
- PHASE3
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
- Status
- COMPLETED
- Phase
- PHASE2
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
- Status
- COMPLETED
- Phase
- PHASE2
1st Line Durvalumab in PS 2 NSCLC Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Trial of Radiotherapy and Durvalumab in DLBCL and FL
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2